Ultromics, an Oxford-based company known for its AI-based cardiology diagnostics, announced the successful completion of a $55 million Series C funding round. The secured funds will enable Ultromics to broaden its market reach and expedite efforts to improve the detection and treatment of complex heart conditions. By leveraging advanced AI algorithms, the company aims to support clinicians in identifying cardiac issues that often go unnoticed through standard procedures.
Historically, Ultromics has been steadily expanding its capabilities and market presence. With FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024 and the introduction of EchoGo Score in 2025 for enhancing the detection of Heart Failure with Preserved Ejection Fraction (HFpEF), the company has seen broad uptake in the United States. Medicare covers these features for both outpatient and inpatient use, solidifying Ultromics’ foothold in the healthcare sector. This latest funding round signifies continued confidence in Ultromics’ ability to innovate within cardiology.
Investment Impact
The investment round was co-led by several major players, including L&G, Allegis Capital, and Lightrock. Both new and existing investors participated, highlighting widespread support for the company’s mission. According to Alastair Stewart, Head of Investments, Venture Capital, at L&G, the market for cardiovascular disease diagnosis remains underserved and presents a substantial opportunity for impactful advancements.
“Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market,” he noted, highlighting the company’s role in pioneering AI-driven echocardiogram technologies.
AI-Driven Diagnostics: How Different Is It?
Ultromics utilizes its EchoGo platform to analyze traditional echocardiograms, facilitating enhanced detection of heart diseases such as HFpEF and cardiac amyloidosis. The AI-driven approach provides probability scores in real time, ensuring quick and accurate risk assessment. The technology seamlessly integrates into existing clinical systems, enabling healthcare professionals to harness its capabilities without additional hardware investments.
By employing machine learning algorithms, the platform allows for precise detection that can aid in earlier intervention. CEO Ross Upton emphasizes the transformative potential of this approach.
“By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier,” he remarked, reinforcing the promise of timely intervention before conditions escalate.
To date, Ultromics has processed over 430,000 echocardiograms, showing improved detection rates. The company’s cardiac amyloidosis model has gained credibility through validation in a study conducted across 18 institutions, with findings published in the European Heart Journal. Furthermore, leading medical establishments such as Mayo Clinic and University Hospitals Cleveland have adopted the technology, underscoring its clinical significance.
In conclusion, Ultromics is channeling its additional funding towards extending its technology to more hospitals and developing solutions for a wider range of cardiac conditions.
The overarching goal is clear, as described by Victor Westerlind of Allegis Capital: “Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier.” Westerlind emphasizes the importance of combining technological advancements with recent treatment innovations to positively impact patient outcomes.
